Clinical Trials Logo

Accelerated/Blast-phase Myeloproliferative Neoplasm clinical trials

View clinical trials related to Accelerated/Blast-phase Myeloproliferative Neoplasm.

Filter by:
  • None
  • Page 1

NCT ID: NCT04281498 Not yet recruiting - IDH2 Mutation Clinical Trials

Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

Start date: March 2021
Phase: Phase 2
Study type: Interventional

The presence of IDH mutation is associated with worse survival in patients with myelofibrosis. Moreover IDH mutations are among the most frequently encountered events in MPNs that have progressed to acute myeloid leukemia. Ruxolitinib, a JAK1/2 inhibitor, and enasidenib an IDH2 inhibitor are effective and tolerable treatments for patients with myelofibrosis (MF) and acute myeloid leukemia (AML), respectively. The study team hypothesize that the combination of these agents in patients with MPN with an IDH2 mutation will improve the overall clinical response to therapy.